Veeda Lifesciences, a global contract research organization (CRO), has announced a strategic investment in Mango Sciences, a Boston-based healthcare AI and data company, to transform clinical trial operations through artificial intelligence. The partnership aims to leverage AI capabilities to enhance the speed, efficiency, and quality of clinical trials services across Veeda's expanded global network, enabling more diverse, efficient recruitment and globally representative patient selection.
AI-Powered Platform Integration
The collaboration centers on deploying Mango Sciences' AI-powered Querent platform, which will automate patient identification with precision and expand Veeda's operational reach across Europe. According to Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited, "Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused in oncology with access to this proprietary technology."
The Querent platform incorporates Large Language Models (LLMs) and Generative-AI technology to drive operational efficiencies and improve real-world evidence. Dr. Mohit Misra, Founder & CEO of Mango Sciences, explained, "We are integrating Large Language Models (LLMs) and Generative-AI into Querent to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient."
Enhancing Clinical Trial Diversity
The partnership specifically addresses the growing regulatory and industry demand for diversity in clinical trials. By deploying the AI-powered platform, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This technological integration is expected to enhance clinical trial efficiency through advanced data analytics, improving patient matching, trial design, and monitoring while reducing costs and timelines.
Strategic Positioning and Expansion
This investment builds on Veeda's previous strategic moves to strengthen its position as a tech-enabled, AI-driven CRO, including the acquisition of Health Data Specialists (Heads). These investments provide Veeda with access to oncology cohorts in India and Europe, along with exclusive access to eligible patient pools. The enhanced capabilities support Veeda's aim to maintain a competitive edge in the CRO sector while delivering comprehensive services to pharmaceutical and biopharmaceutical clients globally.
Technology Modernization Initiative
The partnership aligns with Veeda's broader objectives of investing in technology modernization and digital transformation to enhance operational efficiency and quality assurance across its clinical research operations. The company's platform provides a comprehensive portfolio of services across various stages of the drug development value chain, supporting small and medium biotech and pharmaceutical companies with capabilities ranging from non-clinical and pre-clinical development to clinical pharmacology and clinical trials across different modalities.
Mango Sciences, founded by industry veterans with extensive experience in healthcare, life sciences, and data analytics, is dedicated to transforming patient care through advanced data analytics and solutions. The company is driven by a mission to improve patient representation and access to comprehensive healthcare through innovative AI technologies.
